The effectiveness is a procedural step with no direct financial impact on Vor Biopharma. Monitor for any subsequent prospectus supplements that could indicate accelerated selling by TCG Crossover Funds, which may create near-term overhang. The prior effective shelf from January 2026 covering 13.9M shares remains an additional overhang factor.
Price Chart
Executive Summary
Vor Biopharma's S-3 registration statement (File No. 333-295346) became effective on May 6, 2026, enabling the resale of up to 5,338,078 shares of common stock held by TCG Crossover Funds from a March 2026 private placement. The company will not receive any proceeds from these sales. This is a routine registration rights fulfillment and does not represent new equity issuance or a capital raise for the company.
Key Facts
- S-3 registration (File No. 333-295346) declared effective on May 6, 2026.
- Registration covers 5,338,078 shares of common stock for resale by TCG Crossover Funds.
- Shares were issued in a March 2026 private placement at $14.05 per share ($75M gross).
- Vor Biopharma will not receive any proceeds from the resale.
- This is a routine registration rights fulfillment, not a new capital raise.
- The company has a prior S-3 effective from January 2026 covering 13,876,032 shares from a December 2025 private placement.
Financial Impact
No financial impact on Vor Biopharma; the company receives no proceeds from the resale.
Risk Factors
- Potential near-term selling pressure if TCG Crossover Funds execute resales aggressively.
- Combined overhang from two effective shelves (5.3M + 13.9M shares) could weigh on stock price.
- No new capital raised for the company, limiting upside catalyst from this filing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| EFFECT Filing (Primary) | 9999999995-26-001527 |
| Document: 9999999995-26-001527-index.html | 9999999995-26-001527 |
| Document: 9999999995-26-001527.txt | 9999999995-26-001527 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 11, 2026 7w ago | Press Release | $23.37 $23.24 | ▼ −0.58% | ▲ +0.48% | $18.47 (−20.97%) |
Jul 9, 2026 12w ago | 3 | $19.14 $23.67 | ▲ +23.67% | ▲ +21.24% | $18.47 (−3.50%) |
Jun 11, 2026 16w ago | Institutional Cluster | $14.09 $19.75 | ▲ +40.17% | ▲ +38.28% | $18.47 (+31.09%) |
Jun 8, 2026 16w ago | Press Release | $13.29 $20.10 | ▲ +51.24% | ▲ +49.61% | $18.47 (+38.98%) |
May 7, 2026 21w ago | EFFECT | $16.08 $13.44 | ▼ −16.42% | ▼ −19.55% | $18.47 (+14.86%) |
Apr 27, 2026 22w ago | S-3 | $14.38 $14.10 | ▼ −1.95% | ▼ −7.42% | $18.47 (+28.44%) |
Apr 27, 2026 22w ago | DEFA14A | $14.38 $14.10 | ▼ −1.95% | ▼ −7.42% | $18.47 (+28.44%) |
Mar 27, 2026 27w ago | Press Release | $14.48 $14.12 | ▼ −2.49% | ▼ −15.23% | $18.47 (+27.56%) |
Mar 23, 2026 27w ago | Press Release | $12.15 $15.32 | ▲ +26.09% | ▲ +17.19% | $18.47 (+52.02%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access